Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor

Sponsor
Hebei Medical University Fourth Hospital
Study ID
NCT04282278
Phase
PHASE2
Status
Unknown

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to assess time window, efficacy and safety of patients who receive anti-PD-1 antibody multimodal combination as first-line treatment of advanced solid tumor.

Key Dates

Start date
Jul 16, 2020
Status verified
Dec 2021
Primary completion
Apr 1, 2022
Completion
Apr 1, 2024

Study Design

Enrollment
180 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Group A
  • Experimental: Group B
  • Experimental: Group C

Primary Outcome Measure

PFS [ Time Frame: evaluated in 24 months since the treatment began ]

Central Contacts

Related Studies